Lunai Bioworks unit BioSymetrics teams with BrainStorm Therapeutics on AI-driven neurology target discovery

Lunai Bioworks, Inc.

Lunai Bioworks, Inc.

LNAI

0.00
  • Lunai Bioworks’ BioSymetrics unit signed a strategic collaboration and LOI with BrainStorm Therapeutics to discover neurology drug targets.
  • Work combines BioSymetrics’ AI target discovery with zebrafish validation, BrainStorm’s human-derived brain organoids to generate partnerable CNS programs.
  • Initial focus targets rare genetic epilepsies, Parkinson’s disease; effort integrates BrainStorm’s midbrain organoid model with PPMI dataset analysis.
  • Flagship rare epilepsy program received grant funding from the LouLou Foundation to advance targets toward validation and development-stage assets.
  • LOI sets a framework to expand into additional indications, aiming to move programs to licensing or other partnering structures.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA69603) on May 28, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.